Science Explorer Back to mapMap
Discussion
Institution · Ono Pharmaceutical (Japan)

Most cited papers from Ono Pharmaceutical (Japan)

Ono Pharmaceutical (Japan)

What are the most cited papers from Ono Pharmaceutical (Japan)?

The most cited paper from Ono Pharmaceutical (Japan) is "Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial" (Ken Kato, Byoung Chul Cho, Masanobu Takahashi et al., 2019), with 1,262 citations. Next come "2APB, 2-Aminoethoxydiphenyl Borate, a Membrane-Penetrable Modulator of Ins(1,4,5)P3-Induced Ca2+ Release" (918) and "Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial" (808).

Showing 50 of 60 papers. Every paper with more than 133 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial Ken Kato, Byoung Chul Cho, Masanobu Takahashi et al. · The Lancet Oncology Open access 30 Sep 2019 1,262
2 2APB, 2-Aminoethoxydiphenyl Borate, a Membrane-Penetrable Modulator of Ins(1,4,5)P3-Induced Ca2+ Release Takayuki Maruyama, Toshiya Kanaji, Shinji Nakade et al. · The Journal of Biochemistry Sep 1997 918
3 Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Yoon‐Koo Kang et al. · The Lancet Oncology Open access 11 Jan 2022 808
4 Altered pain perception and inflammatory response in mice lacking prostacyclin receptor Tatsunori Murata, Fumitaka Ushikubi, Toshiyuki Matsuoka et al. · Nature 14 Aug 1997 785
5 Expanded polyglutamine in the Machado–Joseph disease protein induces cell death in vitro and in vivo Hanako Ohashi Ikeda, Masahiro Yamaguchi, Satoshi Sugai et al. · Nature Genetics Jun 1996 551
6 Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-β1 release Kazushi Imai, Ari HIRAMATSU, Daikichi Fukushima et al. · Biochemical Journal Open access 15 Mar 1997 443
7 Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity Markus Hoffmann et al. · EBioMedicine Open access Mar 2021 403
8 The Role of Prostaglandin E Receptor Subtypes (EP1, EP2, EP3, and EP4) in Bone Resorption: An Analysis Using Specific Agonists for the Respective EPs Tetsuo Suzawa, Chisato Miyaura, Masaki Inada et al. · Endocrinology Open access Apr 2000 393
9 Transient receptor potential ( TRP ) channels: a clinical perspective Yosuke Kaneko, ARPAD SZALLASI · British Journal of Pharmacology Open access 8 Oct 2013 371
10 ONO-5046, a novel inhibitor of human neutrophil elastase Kazuhito Kawabata, Mayumi Suzuki, Masafumi Sugitani et al. · Biochemical and Biophysical Research Communications Jun 1991 363
11 Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice Takuya Kobayashi, Yoshio Tahara, Mayumi Matsumoto et al. · Journal of Clinical Investigation Open access 15 Sep 2004 360
12 Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation Keiji Yoshida, Hiroji Oida, Takuya Kobayashi et al. · Proceedings of the National Academy of Sciences Open access 26 Mar 2002 350
13 IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity Seigo Terawaki, Shunsuke Chikuma, Shiro Shibayama et al. · The Journal of Immunology Open access 25 Jan 2011 342
14 The role of neutrophil elastase in acute lung injury Kazuhito Kawabata, Tetsuya Hagio, Shozo Matsuoka · European Journal of Pharmacology Sep 2002 340
15 Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study Makoto Ueno, Masafumi Ikeda, Chigusa Morizane et al. · ˜The œLancet. Gastroenterology & hepatology 17 May 2019 336
16 Host Prostaglandin E2-EP3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor Growth Hideki Amano, Izumi Hayashi, Hirahito Endo et al. · The Journal of Experimental Medicine Open access 20 Jan 2003 330
17 Patent Ductus Arteriosus and Neonatal Death in Prostaglandin Receptor EP4-Deficient Mice Eri Segi‐Nishida, Yukihiko Sugimoto, A. Yamasaki et al. · Biochemical and Biophysical Research Communications May 1998 322
18 A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies Harriet S. Walter et al. · Blood Open access 5 Nov 2015 269
19 Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity Satomi Imaide, Kristin M. Riching, Nikolai Makukhin et al. · Nature Chemical Biology Open access 21 Oct 2021 247
20 Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04) Nobuyuki Katakami, Junji Uchino, Takuma Yokoyama et al. · Cancer Open access 4 Dec 2017 247
21 PD-1-Mediated Suppression of IL-2 Production Induces CD8+ T Cell Anergy In Vivo Shunsuke Chikuma, Seigo Terawaki, Tamon Hayashi et al. · The Journal of Immunology 19 May 2009 247
22 Applications of Bartoli indole synthesis Giuseppe Bartoli, Renato Dalpozzo, Mónica Nardi · Chemical Society Reviews Review 2014 238
23 Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT) Morihito Okada, Takashi Kijima, Keisuke Aoe et al. · Clinical Cancer Research 4 Jun 2019 237
24 A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Li‐Tzong Chen et al. · Gastric Cancer Open access 20 Dec 2019 231
25 Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In Vitro Kenji Maeda, Hirotomo Nakata, Yasuhiro Koh et al. · Journal of Virology Open access 27 Jul 2004 221
26 K2P2.1 (TREK-1)–activator complexes reveal a cryptic selectivity filter binding site Marco Lolicato, Cristina Arrigoni, Takahiro Mori et al. · Nature Open access Jul 2017 216
27 Crystal Structure of Antagonist Bound Human Lysophosphatidic Acid Receptor 1 Jill Chrencik, C. Roth, Masahiko Terakado et al. · Cell Open access Jun 2015 216
28 Evidence that Glyceraldehyde‐3‐Phosphate Dehydrogenase Is Involved in Age‐Induced Apoptosis in Mature Cerebellar Neurons in Culture Ryoichi Ishitani, Katsuyoshi Sunaga, Atsushi Hirano et al. · Journal of Neurochemistry Mar 1996 215
29 Arachidonate 5-lipoxygenase of guinea pig peritoneal polymorphonuclear leukocytes. Activation by adenosine 5'-triphosphate. Kazuhide Ochi, T Yoshimoto, S Yamamoto et al. · Journal of Biological Chemistry Open access May 1983 215
30 Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA) Junzo Hamanishi et al. · Journal of Clinical Oncology Open access 2 Sep 2021 212
31 GPR31-dependent dendrite protrusion of intestinal CX3CR1+ cells by bacterial metabolites Naoki Morita, Eiji Umemoto, Setsuko Fujita et al. · Nature 23 Jan 2019 211
32 Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer Shunichi Sugawara, J.-S. Lee, Jin‐Hyoung Kang et al. · Annals of Oncology Open access 15 Jun 2021 204
33 Using zebrafish in systems toxicology for developmental toxicity testing Yuhei Nishimura, Atsuto Inoue, Shota Sasagawa et al. · Congenital Anomalies 5 Nov 2015 201
34 Development of a Highly Cardioselective Ultra Short-Acting .BETA.-Blocker, ONO-1101. Sadahiko Iguchi, H. IWAMURA, Minoru NISHIZAKI et al. · Chemical and Pharmaceutical Bulletin Open access 1992 198
35 Lysophospholipid receptors in drug discovery Yasuyuki Kihara, Hirotaka Mizuno, Jerold J. M. Chun · Experimental Cell Research Open access 8 Dec 2014 195
36 Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima et al. · Neuro-Oncology Open access 16 Jun 2020 188
37 A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes Hiroyuki Ando, Takashi Yoshinaga, Wataru Yamamoto et al. · Journal of Pharmacological and Toxicological Methods Open access 10 Dec 2016 185
38 Relationship between neutrophil elastase and acute lung injury in humans Shouetsu TAMAKUMA, Michio Ogawa, Naoki Aikawa et al. · Pulmonary Pharmacology & Therapeutics 6 Jul 2004 177
39 Inhibition of skin development by targeted expression of a dominant-negative retinoic acid receptor Mitinori Saitou, Satoshi Sugai, Toshihiro Tanaka et al. · Nature Mar 1995 173
40 Regulation of TNFα and interleukin-10 production by prostaglandins I2 and E2: studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists Shiho Shinomiya, Hiroaki Naraba, Akinori Ueno et al. · Biochemical Pharmacology May 2001 173
41 Structural and Molecular Interactions of CCR5 Inhibitors with CCR5 Kenji Maeda, Debananda Das, Hiromi Ogata-Aoki et al. · Journal of Biological Chemistry Open access 14 Feb 2006 164
42 A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in advanced gastrointestinal cancer patients with cancer cachexia Satoshi Hamauchi, Junji Furuse, Toshimi Takano et al. · Cancer Open access 15 Aug 2019 163
43 Delayed Neutrophil Elastase Inhibition Prevents Subsequent Progression of Acute Lung Injury Induced by Endotoxin Inhalation in Hamsters Kazuhito Kawabata, Tetsuya Hagio, Shigeru Matsumoto et al. · American Journal of Respiratory and Critical Care Medicine Jun 2000 159
44 A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors Toshihiko Doi, Kei Muro, Hiroshi Ishii et al. · Clinical Cancer Research 27 Aug 2019 158
45 Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes Keiichi Asakura, Seiji Hayashi, Atsuko Ojima et al. · Journal of Pharmacological and Toxicological Methods Open access 21 Apr 2015 156
46 Nuclear Localization of Overexpressed Glyceraldehyde-3-Phosphate Dehydrogenase in Cultured Cerebellar Neurons Undergoing Apoptosis Ryoichi Ishitani, Masaharu Tanaka, Katsuyoshi Sunaga et al. · Molecular Pharmacology Apr 1998 155
47 Lipocalin-type prostaglandin D synthase produces prostaglandin D 2 involved in regulation of physiological sleep Weimin Qu, Zhi‐Li Huang, Xin-Hong Xu et al. · Proceedings of the National Academy of Sciences Open access 8 Nov 2006 151
48 Involvement of Leukotriene B4 in Substance P-Induced Itch-Associated Response in Mice Nobuo C. Katsube, Masayuki Maruyama, Tsugunobu Andoh et al. · Journal of Investigative Dermatology Open access Dec 2001 146
49 Effect of lysine and methionine supplementation to a soy protein concentrate diet for red sea bream Pagrus major Shusaku Takagi, Sadao Shimeno, Hidetsuyo Hosokawa et al. · Fisheries Science Open access Dec 2001 146
50 Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial Koichi Takayama, Nobuyuki Katakami, Takuma Yokoyama et al. · Supportive Care in Cancer Open access 23 Mar 2016 144

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.